Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

Breast Neoplasms Clinical Trial

Official title:

Phase II Study Of SKI-606 In Subjects With Advanced Or Metastatic Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00319254
• Other study ID #: 3160A2-201
• Secondary ID: B1871014
• Status: Completed
• Phase: Phase 2
• First received: April 24, 2006
• Last updated: December 21, 2012
• Start date: May 2006
• Est. completion date: February 2009

Study information

• Verified date: December 2012
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if SKI-606 (Bosutinib) is effective in the treatment of advanced or metastatic breast cancer. Patients must have current Stage IIIB, IIIC or IV breast cancer and have progressed after 1 to 3 prior chemotherapy regimens.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: February 2009
• Est. primary completion date: February 2009
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Stage IIIB, IIIC or IV breast cancer not curable with available therapy.

• Patients must have progressed after 1 but not more than 3 prior chemotherapy regimens.

• Life expectancy of at least 16 weeks.

• Ability to swallow whole capsules.

Exclusion Criteria:

• Use of or requirement for bisphosphonates within 8 weeks prior to screening.

• Any other cancer within 5 years of screening, except for basal cell carcinoma or cervical carcinoma in situ

• Uncontrolled cardiac disease including congestive heart failure, angina, heart attack, etc.

• Recent or ongoing significant gastrointestinal disorder

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Neoplasms
• Neoplasm Metastasis
• Neoplasms

Intervention

Drug:
• SKI-606 (Bosutinib)
SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.

Locations

Country	Name	City	State
Australia	Pfizer Investigational Site	Darlinghurst	New South Wales
France	Pfizer Investigational Site	Dijon
France	Pfizer Investigational Site	Saint-Herblain
Hong Kong	Pfizer Investigational Site	Pokfulam
Malta	Pfizer Investigational Site	Floriana
Poland	Pfizer Investigational Site	Lodz
Poland	Pfizer Investigational Site	Wroclaw
Russian Federation	Pfizer Investigational Site	Moscow
Ukraine	Pfizer Investigational Site	Dnipropetrovsk
Ukraine	Pfizer Investigational Site	Sumy
Ukraine	Pfizer Investigational Site	Uzhgorod
United States	Pfizer Investigational Site	Cleveland	Ohio
United States	Pfizer Investigational Site	Duarte	California
United States	Pfizer Investigational Site	Santa Monica	California
United States	Pfizer Investigational Site	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Australia,  France,  Hong Kong,  Malta,  Poland,  Russian Federation,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Population Pharmacokinetics (PK)	Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.	Pre-dose, 2, 7, 20 hours post-dose on Day 1 of Week 4 and pre-dose on Day 1 of Weeks 1, 8, 12, 16, and 24	No
Primary	Progression-Free Survival (PFS) Rate	PFS was based on Kaplan-Meier estimates. PFS was defined as time in weeks from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from death case report forms (CRFs). Percentage of participants who had not experienced progression or death by Week 16 is reported.	Baseline up to Week 16	No
Primary	Percentage of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state.	Baseline up to 30 days after last dose of study treatment	Yes
Secondary	Overall Survival (OS)	OS was estimated by Kaplan-Meier method. Survival was defined as the time period from the date of first dose of study treatment to the date of death, censored at the participant's last contact date. Percentage of participants who were still alive at 2 years is reported.	Baseline up to Year 2	No
Secondary	Percentage of Participants With Objective Response (OR)	Percentage of participants with OR was based on the assessment of confirmed complete remission (CR) or confirmed partial remission (PR) according to sponsor modified Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed CR defined as disappearance of all target and non-target lesions. Confirmed PR defined as more than or equal to (>=) 30% decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD. Confirmed responses are those that persist on repeat imaging study >=4 weeks after initial documentation of response.	Baseline up to Year 1	No
Secondary	Percentage of Participants With Clinical Benefit	Clinical benefit was defined as a confirmed CR or PR, or stable disease (SD) for more than (>) 24 weeks as the best response before the first evidence of progressive disease (PD). A participant demonstrating CR, PR, or SD >24 weeks at any time while on study was counted in the numerator.	Baseline up to end of treatment (Week 77)	No
Secondary	Number of Participants With Change From Baseline in Laboratory Test Results	Number of participants with potentially clinically significant (PCS) laboratory values are reported. Criteria for PCS laboratory values include: aspartate aminotransferase (AST), alanine aminotransferase (ALT) >5*upper limit of normal(ULN) milliunit/milliliter(mU/mL); total bilirubin >3*ULN micromole/L; sodium <130, magnesium <0.4 and >1.23 millimole/L; lipase >2*ULN microkats/L; neutrophils <1*10^9/L. Participants meeting at least 1 PCS criteria are reported.	Baseline up to end of treatment (Week 77)	Yes
Secondary	Number of Participants With Change From Baseline in Electrocardiogram (ECG)	Number of participants with potentially clinically significant (PCS) ECG findings are reported. Criteria for PCS ECG findings include: no sinus rhythm; heart rate >=120 beats per minute (bpm) or increase >=15 bpm; QT interval corrected using Bazett's formula (QTcB) >60 milliseconds (msec) change from baseline; and overall ECG evaluation not normal.	Baseline up to end of treatment (Week 77)	Yes
Secondary	Number of Participants With Change From Baseline in Vital Signs, Physical Examinations, and Ophthalmological Examinations	Number of participants with potentially clinically significant (PCS) vital signs and physical examinations are reported. Criteria for PCS vital signs include: respiratory rate >25 breaths/minute and PCS physical examinations include: an increase or decrease from baseline of >=7% in body weight.	Baseline up to end of treatment (Week 77)	Yes
Secondary	Concomitant Medications Used for Management of Adverse Events (AEs)	Number of participants taking any non-study medications which were administered from Study Day 1 to last dose of study treatment (Week 77) as a management of an AE were to be reported.	Day 1 up to end of treatment (Week 77)	Yes
Secondary	Change From Baseline in Karnofsky Performance Status (KPS) at Week 1, 4, 8, 12, 16, Every 8 Weeks Thereafter and 14 Days After Last Dose of Study Treatment	KPS: 11 level score ranged 100 to 0, to assess functional impairment. 100:Normal; 90:Able to carry on normal activity; 80:Normal activity with effort, some signs or symptoms of disease; 70:Cares for self, unable to carry on normal activity or to do active work; 60:Requires occasional assistance but is able to care for most of needs; 50:Requires considerable assistance and frequent medical care; 40:Disabled,requires special care and assistance; 30:Severely disabled; hospitalization indicated although death is not imminent; 20:Very sick; 10:Morbibund,fatal processes progressing rapidly; 0:Death.	Baseline, Weeks 1,4,8,12,16, every 8 weeks thereafter and 14 days after last dose of study treatment	Yes

External Links

•   To obtain contact information for a study center near you, click here.